fig2

Figure 2. CONSORT flow-chart. Sixty-six PMS patients were assessed for eligibility. Thirty-five of them were recruited and randomized into groups receiving either active compound (n = 18) or active comparator (n = 17) during the first 4 months. Thirty-three patients completed the entire study, whereas one patient dropped out of each treatment group during the first 4-month period.